Physician profile
Mark Townsend
NPI 1497778351
$1,096.74
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $182 · 2021: $247 · 2022: $74.52.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $262.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $223.77 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $151.30 | 2019 | |
| Abbvie INC. | $95.18 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $70.22 | 2019-2021 | |
| Lundbeck LLC | $69.54 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $63.72 | 2019-2021 | |
| Alkermes, INC. | $45.04 | 2021 | |
| Shire North American Group INC | $42.49 | 2019 | |
| Vanda Pharmaceuticals INC. | $33.06 | 2019 | |
| Neurocrine Biosciences, INC. | $28.14 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.83 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.